期刊文献+

替格瑞洛联合阿司匹林在冠心病介入治疗患者中的应用效果观察 被引量:4

下载PDF
导出
摘要 目的观察冠心病介入治疗患者应用替格瑞洛联合阿司匹林的临床效果。方法选取2017年1月-2018年5月在医院治疗的冠心病介入治疗患者72例,随机分为观察组与对照组各36例。对照组给予阿司匹林治疗,观察组在对照组的基础上给予替格瑞洛治疗。比较2组患者凝血功能指标、心血管不良事件发生情况及血小板最大聚集率(MPAR)。结果术后3 d,观察组患者凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)低于对照组,凝血酶时间(TT)高于对照组,差异均有统计学意义(P<0.05)。观察组治疗后3及6个月的心血管不良事件发生率均低于对照组,差异均有统计学意义(P<0.05)。术后3 d观察组患者MPAR低于对照组,差异有统计学意义(P<0.05)。结论替格瑞洛联合阿司匹林在冠心病介入治疗中的应用效果较好,能有效改善患者凝血功能,减少术后心血管不良事件,改善供血不足。
出处 《临床合理用药杂志》 2019年第31期43-44,共2页 Chinese Journal of Clinical Rational Drug Use
  • 相关文献

参考文献7

二级参考文献60

  • 1Becker RC, Gurbel PA. Platelet P2Y12 receptor antagonist pharmacokinetics and phannacodynamics : a foundation for distinguishing mechanisms of bleeding and anticipated risk for platelet-directed therapies[J]. Thromb Haemost,2010, 103(3) :535-544.
  • 2Husted S. Unmet needs in oral antiplatelet therapy with ADP receptor blocking agents [ J ]. Fundam Clin Pharmaeol,2009,23 ( 1 ) : 1-9.
  • 3Windecker S, Kolh P, Alfonso F, et ah 2014 ESC/EACTS Guidelines on myo- cardial revascularization : The Task Force on Myocardial Revascularization of the European Society of Cardiology(ESC) and the European Association for Cardio- Thoracic Surgery (EACTS) Developed with the special contribution of the Euro- pean Association of Percutaneoas Cardiovascular Interventions ( EAPCI ) [ J ]. Eur Heart J,2014,35(37) :2541-2619.
  • 4Chang JW. Tieagrclor: oral reversible P2Y (12) receptor antagonist for the management of acute coronary syndromes [ J 1. Clin Tber, 2012,34 ( 6 ) : 1209- 1220.
  • 5Gurbel PA, Bliden KP, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopi- dogrel in patients with stable coronary artery disease: the ONSET/OFFSET study[J]. Cireulation,2009,120(25) :2577-2585.
  • 6Wallcntin L, Becke RC, Buda A, et al. Ticagrelor versus clopidogrel in pa- tients with acute coronary syndromes[ J]. N Engl J Med,2009,361 (11 ) :1045- 1057.
  • 7Held C, Asenbtad N, Bassand JP, et at. Ticagrelor versus clopidogrel in pa- tients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial[ J ]. J Am Coil Cardiol,2011,57 (6) :672 -684.
  • 8Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in pa- tients with ST-elevation acute coronary syndromes intended for reperfusion with primary pereutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis[J]. Circulation,2010,122(21) : 2131-2141.
  • 9Lindholm D, Varenhorst C, Cannon CP, et al. Ticagrelor vs. clopidogrel in pa- tients with non-ST-elevation acute coronary syndrome with or without revascular- ization: results from the PLATO trial[ J ]. Eur Heart J, 2014,35 (31) :2083- 2093.
  • 10de Luca G, Suryapranata H, Ottervanger JP, et al. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction:every minute of delay counts[J]. Circulation,2004,109(10) :1223-1225.

共引文献107

同被引文献45

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部